PharmaBlock, a leading company based in Nanjing (SHE: 300725), has announced the opening of a new R&D facility in West Chester, Pennsylvania. This strategic move aims to expand the company’s presence in the United States and offer more efficient process R&D services, enabling the fast delivery of clinical-stage GMP projects to global partners.
Features and Capabilities of the West Chester Facility
The West Chester site, spread over four acres, offers 30,000 square feet of usable lab space and boasts a well-established R&D infrastructure. It includes process R&D labs, GMP suites, clean rooms, and GMP analytical labs. The new site is equipped to provide flow chemistry, micro-packed bed hydrogenation, and solid-state chemistry capabilities, enhancing PharmaBlock’s service offerings in the U.S. market.
PharmaBlock’s US Market Expansion History
PharmaBlock entered the US market in 2012 with the establishment of a sales and customer service office in the Bay Area of California. In 2017, the company expanded its operations by establishing a process R&D facility in Hatfield, Pennsylvania, which provides 15,000 square feet of lab space and is fully equipped with process R&D labs and GMP kilo-labs. Several API and GMP projects have been successfully delivered to US-based clients from this site, solidifying PharmaBlock’s reputation in the industry.
Enhancing Clinical-Stage API Project Delivery
The West Chester site is a vital addition to PharmaBlock’s global operations, enhancing the delivery of clinical-stage API projects at PharmaBlock USA. Furthermore, the company plans to establish a GMP manufacturing facility for intermediates and APIs at the West Chester site, with reactors ranging from 500 L to 2,000 L. This new facility is expected to commence operations in 2024, further bolstering PharmaBlock’s capabilities to serve the global pharmaceutical market.-Fineline Info & Tech